About Tercica
Tercica is a Healthcare company based in Brisbane (United States) founded in 2002 by Ross Clark. Therapeutics for the treatment of endocrine and metabolic diseases. Tercica has raised $65.5 million across 2 funding rounds from investors including Genentech, Rho Capital Partners and Care Capital. The company has since been acquired. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its competitors include Neurocrine, Crinetics and MBX Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Tercica is a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica had strategic partnerships with Genentech and Ipsen. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen
- Headquarters Brisbane, United States
- Founders Ross Clark
- Stage Acquired
- SectorsHealthcare
- Website tercica.com
- Social LinkedIn
- Total Equity Funding$65.5M (USD)
in 2 rounds
- Latest Funding Round$44M (USD), Series B
Jul 2003
- InvestorsGenentech
& 5 more
Funding Insights of Tercica
Tercica has successfully raised a total of $65.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $44 million completed in July 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.5M
- Total Rounds 2
- Last Round Series B — $44M
- First Round $21.5M
(Mar 2002)
- Investors Count 6
All 2 funding rounds of Tercica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2003 | $44M | Series B | – | – | |
| Mar 2002 | $21.5M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Tercica
Tercica has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, Rho Capital Partners and Care Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
| carecapital.com | ||||
| medimmuneventures.com | ||||
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Tercica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tercica
1 people are tracked at Tercica (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ross Clark | Founder | Leadership |
Complete people profiles for Tercica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Tercica
4 dated milestones of Tercica across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Tercica is founded.
- Funding First funding round of $21.5M.
- Funding Latest funding round, Series B, of $44.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Tercica
Tercica has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and MBX Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| mbxbio.com | 2018 | Carmel, United States | $215.6M | 11 | Drugs for rare endocrine diseases are developed and advanced. |
Detailed competitors of Tercica
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tercica
Websites that share an audience with Tercica (tercica.com).
Websites whose visitors overlap most with Tercica. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
epochbiolabs.com | epochbiolabs.com | 100% | – | ||
alexionpharmaceuticals.com | alexionpharmaceuticals.com | 100% | – | ||
| biosource.com | 100% | View details | |||
| prospecbio.com | 100% | 53.2K | #651,600 | View details | |
cytokinecenter.com | cytokinecenter.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Tercica
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Tercica (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tercica
Complete news archive for Tercica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tercica
Tercica was founded in 2002.
Tercica is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
Tercica is a funded company, having raised a total of $65.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $21.5M, raised on Mar 2002.
Tercica is a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica had strategic partnerships with Genentech and Ipsen. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen.
Tercica's top competitors include Crinetics, Neurocrine and MBX Biosciences.
Tercica has 6 investors. Key investors include Genentech, Rho Capital Partners, Care Capital, MedImmune Ventures, and Turmeric Acquisition Corp.